Skip to main content
Clinical Trials/NCT03490058
NCT03490058
Completed
Not Applicable

A Cohort for Evaluation of Open-label PrEP Delivery Among Kenyan and South African Women: The POWER Cohort

University of Washington3 sites in 2 countries2,255 target enrollmentJune 14, 2017
ConditionsHIV/AIDS
InterventionsTruvada
DrugsTruvada

Overview

Phase
Not Applicable
Intervention
Truvada
Conditions
HIV/AIDS
Sponsor
University of Washington
Enrollment
2255
Locations
3
Primary Endpoint
Demonstrate PrEP delivery models for young women in different settings and geographies.
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The POWER Cohort study is a PrEP implementation project to demonstrate Pre-exposure prophylaxis (PrEP) delivery for young women in Cape Town and Johannesburg, South Africa and Kisumu, Kenya.

Detailed Description

PrEP will be delivered to young women according to emerging national guidelines in family planning clinics (Kisumu, Kenya), youth friendly clinics (Johannesburg, South Africa), and mobile youth friendly clinics (Cape Town, South Africa). The investigators will evaluate PrEP delivery and follow cohorts of young women at each clinic location to understand PrEP uptake and use. In the Kisumu clinics, the investigators will also offer expedited partner therapy and partner HIV self-tests to women who test positive for chlamydia and/or gonorrhea. At one clinic in Johannesburg, the investigators will evaluate the use of a decision support tool to improve the decision to initiate PrEP.

Registry
clinicaltrials.gov
Start Date
June 14, 2017
End Date
July 23, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Connie Celum

Prof of Medicine & Global Health, Adjunct Prof of Epidemiology, SOM: Global Health

University of Washington

Eligibility Criteria

Inclusion Criteria

  • Age 16-25 (16 and 17 year olds, where permissible by national regulations and local IRB approval)
  • Able and willing to provide written informed consent
  • Recently sexually active (defined as having had vaginal intercourse at least once in the previous three months)
  • HIV uninfected based on negative HIV rapid tests, on the date of enrollment

Exclusion Criteria

  • Not provided

Arms & Interventions

Young women

Sexually active HIV-uninfected women between 16-25 years of age will be given Truvada.

Intervention: Truvada

Outcomes

Primary Outcomes

Demonstrate PrEP delivery models for young women in different settings and geographies.

Time Frame: Up to 36 months

Mixed methods assessment of how PrEP is implemented at the user, provider, health care facility, and community levels.

Secondary Outcomes

  • PrEP initiation(Up to 36 months)
  • PrEP adherence(Up to 36 months)
  • HIV seroconversion(Up to 36 months)

Study Sites (3)

Loading locations...

Similar Trials